300683.SZ Stock Analysis
30
Uncovered
Wuhan Hiteck Biological Pharma Co Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Wuhan Hiteck Biological Pharma Co., Ltd. engages in the research, development, production, and sale of chemicals including biological products and thrombin. The company is headquartered in Wuhan, Hubei and currently employs 1,143 full-time employees. The company went IPO on 2017-08-08. The firm operates five segments. The Biopharmaceutical segment is engaged in research, development, production and sales of biological products, and its primary product is mouse nerve growth factor for injection named Jinlujie. The Medical Technology Service segment is mainly involved in the technical development, technical consultation and technology transfer of chemical drugs. The In Vitro Diagnostic Reagents segment operates the research, development, production and sales of in vitro diagnostic reagents. The Pharmaceutical Sales and Wholesale segment is engaged in the sales and wholesale of pharmaceuticals. The Other segment’s businesses include the cultivation and sales of Chinese herbal medicines, and the wholesale and retail of health products.